Comparative safety of sulfonylureas and the risk of sudden cardiac arrest and ventricular arrhythmia

Diabetes Care

Volumn 41, Issue 4, 2018, Pages 713-722

  Leonard, Charles E ^a   Brensinger, Colleen M ^a   Aquilante, Christina L ^b   Bilker, Warren B ^a   Boudreau, Denise M ^c,d   Deo, Rajat ^a,e   Flory, James H ^a,f,g   Gagne, Joshua J ^h   Mangaali, Margaret J ^a   Hennessy, Sean ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c KAISER PERMANENTE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f Department of Obstetrics Gynecology   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; SULFONYLUREA DERIVATIVE;

AGED; CAUSE OF DEATH; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; DIABETIC ANGIOPATHY; FEMALE; HEART ARRHYTHMIA; HEART VENTRICLE FUNCTION; HUMAN; HYPOGLYCEMIA; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; SUDDEN CARDIAC DEATH; UNITED STATES;

AGED; ARRHYTHMIAS, CARDIAC; CAUSE OF DEATH; DEATH, SUDDEN, CARDIAC; DIABETIC ANGIOPATHIES; FEMALE; GLIPIZIDE; GLYBURIDE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SULFONYLUREA COMPOUNDS; UNITED STATES; VENTRICULAR DYSFUNCTION;

EID: 85044539301     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-0294     Document Type: Article

References (79)

1. Lopshire JC, Zipes DP. Sudden cardiac death: Better understanDing of risks, mechanisms, and treatment. Circulation 2006;114:1134-1136
2. Hayashi M, Shimizu W, Albert CM. The spectrum of epidemiology underlying sudden cardiac death. Circ Res 2015;116:1887-1906
3. Tomaselli GF. Introduction to a compendium on sudden cardiac death: Epidemiology, mechanisms, and management. Circ Res 2015;116: 1883-1886
4. Bergner DW, Goldberger JJ. Diabetes mellitus and sudden cardiac death: What are the data Cardiol J 2010;17:117-129
5. Deo R, Albert CM. Epidemiology and genetics of sudden cardiac death. Circulation 2012;125: 620-637
6. Albert CM, Chae CU, Grodstein F, et al. Prospective study of sudden cardiac death among women in the United States. Circulation 2003; 107:2096-2101
7. Bayés de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: Mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989;117:151-159
8. Greene HL. Sudden arrhythmic cardiac death-mechanisms, resuscitation and classification: The Seattle perspective. Am J Cardiol 1990;65:4B-12B
9. Siscovick DS, Sotoodehnia N, Rea TD, Raghunathan TE, Jouven X, Lemaitre RN. Type 2 diabetes mellitus and the risk of sudden cardiac arrest in the community. Rev Endocr Metab Disord 2010;11:53-59
10. El-Atat FA, Mc Farlane SI, Sowers JR, Bigger JT. Sudden cardiac death in patients with diabetes. Curr Diab Rep 2004;4:187-193
11. Leonard CE, Hennessy S, Han X, Siscovick DS, Flory JH, Deo R. Pro-A nd anti-arrhythmic actions of sulfonylureas: Mechanistic and clinical evidence. Trends Endocrinol Metab 2017;28:561-586
12. Suarez GA, Clark VM, Norell JE, et al. Sudden cardiac death in diabetes mellitus: Risk factors in the Rochester diabetic neuropathy study. J Neurol Neurosurg Psychiatry 2005;76:240-245
13. De Ponti F, Poluzzi E, Vaccheri A, et al. Nonantiarrhythmic drugs prolonging the QT interval: Considerable use in seven countries. Br J Clin Pharmacol 2002;54:171-177
14. El-Menyar AA. Dysrhythmia and electrocardiographic changes in diabetes mellitus: Pathophysiology and impact on the incidence of sudden cardiac death. J Cardiovasc Med (Hagerstown) 2006;7:580-585
15. Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA 2015;314:1818-1831
16. Lipska KJ, Yao X, Herrin J, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006-2013. Diabetes Care 2017; 40:468-475
17. Sola D, Rossi L, Schianca GP, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci 2015; 11:840-848
18. Schotborgh CE, Wilde AA. Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients. Cardiovasc Res 1997;34:73-80
19. Brady PA, Terzic A. Thesulfonylureacontroversy: More questions from the heart. J Am Coll Cardiol 1998;31:950-956
20. Zünkler BJ. Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassiumchannels as targets for adverse drug effects. Pharmacol Ther 2006;112:12-37
21. Leonard CE, Bilker WB, Brensinger CM, et al. Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics. Clin Pharmacol Ther 2016;99:538-547
22. Stahn A, Pistrosch F, Ganz X, et al. Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: Silent hypoglycemias and silent arrhythmias. Diabetes Care 2014;37: 516-520
23. Varvaki Rados D, Catani Pinto L, Reck Remonti L, Bauermann Leitaõ C, Gross JL. The association between sulfonylurea use and all-cause and cardiovascular mortality: A meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med 2016;13:e1001992
24. Pladevall M, Riera-Guardia N, Margulis AV, Varas-Lorenzo C, Calingaert B, Perez-Gutthann S. Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: Metaanalysis of published observational studies. BMC Cardiovasc Disord 2016;16:14
25. Simpson SH, Lee J, Choi S, Vandermeer B, Abdelmoneim AS, Featherstone TR. Mortality risk among sulfonylureas: A systematic review and network meta-analysis. Lancet Diabetes Endocrinol 2015;3:43-51
26. Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: A meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15:938-953
27. Hemmingsen B, Schroll JB, Wetterslev J, et al. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: A Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open 2014;2:E162-E175
28. Bain S, Druyts E, Balijepalli C, et al. Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data. Diabetes Obes Metab 2017;19:329-335
29. Ahr én B, Johnson SL, Stewart M, et al.; HARMONY 3 Study Group. HARMONY 3: 104-week randomized, double-blind, placebo-A nd activecontrolled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care 2014;37:2141-2148
30. Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: A 2-year study. Diabetes Obes Metab 2014; 16:1239-1246
31. Ridderstr°ale M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC; EMPA-REG H2H-SU trial investigators. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: A 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014;2:691-700
32. Frye RL, August P, Brooks MM, et al.; BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503-2515
33. Engler RL, Yellon DM. Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration. Circulation 1996;94:2297-2301
34. Shimoda M, Kaku K. Controversy about the relationship between sulfonylurea use and cardiovascular events and mortality. J Diabetes Investig 2016;7:674-676
35. Liberthson RR. Sudden death from cardiac causes in children and young adults. N Engl J Med 1996;334:1039-1044
36. Hennessy S, Leonard CE, Palumbo CM, Newcomb C, Bilker WB. Quality of Medicaid and Medicare data obtained through Centers for Medicare and Medicaid Services (CMS). Med Care 2007;45:1216-1220
37. Leonard CE, Brensinger CM, Nam YH, et al. The quality of Medicaid and Medicare data obtained from CMS and its contractors: Implications for pharmacoepidemiology. BMC Health Serv Res 2017;17:304
38. Standards ofmedical care in diabetesd2016: Summary of revisions. Diabetes Care 2016;39 (Suppl. 1):S4-S5
39. Zhou M, Wang SV, Leonard CE, et al. Sentinel modular program for propensity-score matched cohort analyses: Application to glyburide, glipizide, and serious hypoglycemia. Epidemiology 2017;28: 838-846
40. Credible Meds. Congenital LQTS and drugs to avoid list [Internet], 2017. Available from https://www.crediblemeds.org/everyone/congenitallong-qt-and-drugs-avoid/. Accessed 29 January 2018
41. Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol 2008;168:329-335
42. Lund JL, Richardson DB, Stürmer T. The active comparator, new user study design in pharmacoepidemiology: Historical foundations and contemporary application. Curr Epidemiol Rep 2015;2:221-228
43. Pantalone KM, Kattan MW, Yu C, et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: A retrospective analysis. Diabetes Obes Metab 2012;14: 803-809
44. Law V, Knox C, Djoumbou Y, et al. Drug Bank 4.0: ShedDing new light on drug metabolism. Nucleic Acids Res 2014;42:D1091-D1097
45. Toh S, Garcá Rodŕguez LA, Hernán MA. ConfounDing adjustment via a semi-automated high-dimensional propensity score algorithm: An application to electronic medical records. Pharmacoepidemiol Drug Saf 2011;20:849-857
46. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009;20:512-522
47. Rassen JA, Doherty M, Huang W, Schneeweiss S. Pharmacoepidemiology toolbox [Internet], 2017. Available from http://www.drugepi.org/dopedownloads/# Pharmacoepidemiology%20Toolbox. Accessed 29 January 2018
48. Mc Murray J. Prophylactic class III antiarrhythmic drug therapy after myocardial infarction: ALIVE or dead In Cardiology Scientific Update. Boston, MA, SNELL Medical Communication, Inc., 2002 (report no. 402-010)
49. Hennessy S, Leonard CE, Freeman CP, et al. Validation of diagnostic codes for outpatientoriginating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data. Pharmacoepidemiol Drug Saf 2010; 19:555-562
50. Chugh SS, Jui J, Gunson K, et al. Current burden of sudden cardiac death:multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol 2004; 44:1268-1275
51. Rassen JA, Glynn RJ, Brookhart MA, Schneeweiss S. Covariate selection in highdimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol 2011;173:1404-1413
52. Austin PC. Goodness-of-fit diagnostics for the propensity score model when estimating treatment effects using covariate adjustment with the propensity score. Pharmacoepidemiol Drug Saf 2008;17:1202-1217
53. Brookhart MA, Wyss R, Layton JB, Stürmer T. Propensity score methods for confounDing control in nonexperimental research. Circ Cardiovasc Qual Outcomes 2013;6:604-611
54. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;1:41-55
55. Austin PC. Absolute risk reductions and numbers needed to treat can be obtained from adjusted survival models for time-to-event outcomes. J Clin Epidemiol 2010;63:46-55
56. Rea TD, Pearce RM, Raghunathan TE, et al. Incidence of out-of-hospital cardiac arrest. Am J Cardiol 2004;93:1455-1460
57. Pogátsa G, Koltai MZ, Balkányi I, Dévai I, Kiss V, Köszeghy A. The effect of various hypoglycaemic sulphonylureas on the cardiotoxicity of glycosides and arrhythmogenic activity due to myocardial ischaemia. Acta Physiol Hung 1988; 71:243-250
58. Cacciapuoti F, Spiezia R, Bianchi U, Lama D, Davino M, Varricchio M. Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus. Am J Cardiol 1991;67:843-847
59. Lomuscio A, Vergani D, Marano L, Castagnone M, Fiorentini C. Effects of glibenclamide on ventricular fibrillation in non-insulin-dependent diabetics with acute myocardial infarction. Coron Artery Dis 1994;5:767-771
60. Aronson D, Mittleman MA, Burger AJ. Effects of sulfonylurea hypoglycemic agents and adenosine triphosphate dependent potassium channel antagonists on ventricular arrhythmias in patients with decompensated heart failure. Pacing Clin Electrophysiol 2003;26:1254-1261
61. Davis TM, Parsons RW, Broadhurst RJ, Hobbs MS, Jamrozik K. Arrhythmias and mortality after myocardial infarction in diabetic patients. Relationship to diabetes treatment. Diabetes Care 1998;21:637-640
62. Ikeda T. QT prolongation in type 2 diabetes mellitus treated with glibenclamide. Diabete Metab 1994;20:565-567
63. Rosati B, Rocchetti M, Zaza A, Wanke E. Sulfonylureas blockade of neural and cardiac HERG channels. FEBS Lett 1998;440:125-130
64. Najeed SA, Khan IA, Molnar J, Somberg JC. Differential effect of glyburide (glibenclamide) and metformin on QT dispersion: A potential adenosine triphosphate sensitive K+ channel effect. Am J Cardiol 2002;90:1103-1106
65. Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 1989;69:1049-1169
66. Riveline JP, Danchin N, Ledru F, Varroud-Vial M, Charpentier G. Sulfonylureas and cardiovascular effects: Fromexperimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab 2003;29:207-222
67. Valensi P, Slama G. Sulphonylureas and cardiovascular risk: Facts and controversies. Br J Diabetes Vasc Dis 2006;6:159-165
68. Vegh A, Papp JG, Szekeres L, Parratt JR. Are ATP sensitive potassium channels involved in the pronounced antiarrhythmic effects of preconditioning Cardiovasc Res 1993;27:638-643
69. Pantalone KM.Doesmortality risk vary among sulfonylureas Lancet Diabetes Endocrinol 2015;3: 6-7
70. Bunch TJ, White RD, Bruce GK, et al. Prediction of short-A nd long-term outcomes by electrocardiography in survivors of out-of-hospital cardiac arrest. Resuscitation 2004;63:137-143
71. Manfredini R, Portaluppi F, Grandi E, Fersini C, Gallerani M. Out-of-hospital sudden death referring to an emergency department. J Clin Epidemiol 1996;49:865-868
72. Myerburg RJ, Kessler KM, Zaman L, Conde CA, Castellanos A. Survivors of prehospital cardiac arrest. JAMA 1982;247:1485-1490
73. Kim C, Fahrenbruch CE, Cobb LA, Eisenberg MS. Out-of-hospital cardiac arrest in men and women. Circulation 2001;104:2699-2703
74. Bunch TJ, Hammill SC, White RD. Outcomes after ventricular fibrillation out-of-hospital cardiac arrest: ExpanDing the chain of survival. Mayo Clin Proc 2005;80:774-782
75. Fox CS, Evans JC, Larson MG, et al. A comparison of death certificate out-of-hospital coronary heart disease death with physician-adjudicated sudden cardiac death. Am J Cardiol 2005;95: 856-859
76. Iribarren C, Crow RS, Hannan PJ, Jacobs DR Jr, Luepker RV. Validation of death certificate diagnosis of out-of-hospital sudden cardiac death. Am J Cardiol 1998;82:50-53
77. Hennessy S, Freeman CP, Cunningham F. US government claims databases. In Pharmacoepidemiology. 5th ed. Strom BL, Kimmel SE, Hennessy S, Eds. Hoboken, NJ, Wiley-Blackwell, 2012, p. 209
78. Leonard CE, Freeman CP, Razzaghi H, et al. Mini-sentinel methods: 15 cohorts of interest for surveillance preparedness [article online]. 2014. Available from https://www.sentinelinitiative.org/sentinel/methods/332. Accessed 16 August 2017
79. Klompas M, Eggleston E, Mc Vetta J, Lazarus R, Li L, Platt R. Automated detection and classification of type 1 versus type 2 diabetes using electronic health record data. Diabetes Care 2013;36: 914-921